- Highlights
- Salk scientists find B cells can promote killer T cell function in a mouse model of an aggressive breast cancer, and that the antitumor benefit of CD40 agonist treatment depends on B cells
- Study addresses the major gap in research around B cells that has limited their clinical potential
- Findings help explain why B cell responses are associated with favorable patient outcomes and provide a foundation for testing B cell-centered immunotherapy strategies
LA JOLLA—Cancer is the second leading cause of death in the United States, according to a 2026 Cancer Research Institute report. Cancer biologists are keenly aware of this statistic, as it drives them to innovations that revolutionize cancer care—innovations like immunotherapy. Immunotherapy fights cancer using the body’s own immune system, and often by boosting the performance of specialized adaptive immune cells called T cells.
Yet not all patients benefit from standard-of-care…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
